Today's Dead Cat Bounce Stock Is Idera Pharmaceuticals (IDRA)
at The Street - Fri Apr 11, 9:10AM CDT
Trade-Ideas LLC identified Idera Pharmaceuticals (IDRA) as a "dead cat bounce" (down big yesterday but up big today) candidate
Top Gainers Technical Data -- Research on BioScrip, E-House China Holdings, MagneGas, and Idera Pharma
PR Newswire - Wed Apr 09, 7:47AM CDT
On Tuesday, April 08, 2014, the US markets saw a positive sentiment, with the NASDAQ Composite closing at 4,112.99, up 0.81%, the Dow Jones Industrial Average ending the session at 16,256.14, up 0.06%, and the S&P 500 edging 0.38% higher to finish the trading session at 1,851.96. The session saw a positive impact from Consumer Discretionary, Energy and Utilities sectors along with a drag from Health Care, Industrials and Telecommunication Services sectors. A number of stocks saw large movements, including BioScrip Inc. (NASDAQ: BIOS), E-House China Holdings Ltd (NYSE: EJ), MagneGas Corp. (NASDAQ: MNGA) and Idera Pharmaceuticals Inc. (NASDAQ: IDRA). Free technical research on BIOS, EJ, MNGA and IDRA can be downloaded upon signing up at:
Idera Presents Preclinical Data at AACR Showing IMO-8400 Inhibits Tumor Growth and Survival Signaling in B-cell Lymphoma Cells with Oncogenic MYD88 L265P Mutation
Business Wire - Mon Apr 07, 3:05PM CDT
--- IMO-8400 in Phase 1/2 trial for Waldenstrom's macroglobulinemia -
Patient Enrollment, Acquisitions, FDA Reviews, and Results of Earnings and Clinical Trials - Analyst Notes on Arrowhead, Providence, Durata, Orthofix, and Idera
PR Newswire - Fri Apr 04, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Arrowhead Research Corp. (NASDAQ: ARWR), Providence Service Corp. (NASDAQ: PRSC), Durata Therapeutics, Inc. (NASDAQ: DRTX), Orthofix International N.V. (NASDAQ: OFIX), and Idera Pharmaceuticals, Inc. (NASDAQ: IDRA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Idera Pharmaceuticals, Inc. Bouncing on Phase 2 Success
Catherine Shaffer, The Motley Fool - Motley Fool - Tue Apr 01, 5:30PM CDT
Idera Pharmaceuticals ' stock market rollercoaster ride left it partially recovered from its 25% plunge just over a week ago upon FDA approval of a competing product developed by Celgene . Idera's plaque psoriasis candidate, IMO-8400, gave good...
Idera Pharmaceuticals (IDRA) Marked As A Dead Cat Bounce Stock
at The Street - Tue Apr 01, 8:48AM CDT
Trade-Ideas LLC identified Idera Pharmaceuticals (IDRA) as a "dead cat bounce" (down big yesterday but up big today) candidate
Why MannKind, Momenta Pharmaceuticals, and Idera Pharmaceuticals Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - Mon Mar 31, 7:30PM CDT
Lately, the stock market has turned on every word from the Federal Reserve, and so this morning's comments from Federal Reserve Chairwoman Janet Yellen received a huge amount of attention from investors Monday. With Yellen offering a much more...
Idera Soars on Phase II Drug Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 31, 4:06PM CDT
Idera announced positive top-line data from a phase II study on IMO-8400.
Biggest Biotech Clinical Wins of the Week
Cory Renauer, The Motley Fool - Motley Fool - Mon Mar 31, 1:30PM CDT
Last week was full of great news for biotechs. Idera Pharmaceuticals finally had some luck with a troubled program. Clovis Oncology took a big step toward treating defined populations with unmet need with a drug and diagnostic combination....
Stock to Watch: Idera Pharmaceuticals Down 6.3% (IDRA)
Comtex SmarTrend(R) - Mon Mar 31, 11:41AM CDT
Idera Pharmaceuticals (NASDAQ:IDRA) is one of today's worst performing low-priced stocks, down 6.3% to $4.28 on 1.1x average daily volume. Thus far today, Idera Pharmaceuticals has traded 3.9 million shares, vs. average volume of 3.6 million shares per day. The stock has underperformed the Dow (-6.3% to the Dow's 0.9%) and underperformed the S&P 500 (-6.3% to the S&P's 0.9%) during today's trading.
BlackBerry Wins Preliminary Injunction against Ryan Seacrest's Typo Products; Red Hat Tumbles on Weak Guidance
ACCESSWIRE - Sun Mar 30, 11:17PM CDT
BlackBerry Limited (NASDAQ: BBRY) - For an in-depth report on BlackBerry Limited follow: www.BullTrends.com/stockquote/BBRY
This Week in Biotech: Biogen Idec Gets a Key Approval While Insmed Confuses Investors
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 29, 2:15PM CDT
With the SPDR S&P Biotech Index up 38% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Why Idera Pharmaceuticals, Bofi Holdings, and Eastman Kodak Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Fri Mar 28, 4:15PM CDT
Following day after day of mixed economic data this week, the broad-based S&P 500 managed to muster up a solid gain on Friday after all data finally pointed in the correct direction. First off, the final Thomson Reuters/University of...
Why Idera Pharmaceuticals Inc. Shares Jumped
Sean Williams, The Motley Fool - Motley Fool - Fri Mar 28, 12:34PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Idera Pharmaceuticals , a clinical-stage...
Idera Pharmaceuticals Announces Positive Top-line Data in Phase 2 Trial of IMO-8400
Business Wire - Fri Mar 28, 6:15AM CDT
--IMO-8400 also demonstrates clinical proof-of-concept in psoriasis
Idera Pharmaceuticals Down 9.2%, Shares Slide into the Red (IDRA)
Comtex SmarTrend(R) - Thu Mar 27, 11:41AM CDT
Idera Pharmaceuticals (NASDAQ:IDRA) is one of today's worst performing low-priced stocks, down 9.2% to $3.81 on 1.1x average daily volume. Idera Pharmaceuticals has traded 3.7 million shares thus far today, vs. average volume of 3.3 million shares per day. The stock has underperformed the Dow (-9.2% to the Dow's 0.0%) and underperformed the S&P 500 (-9.2% to the S&P's -0.2%) during today's trading.
Is Idera's Sell-Off Premature?
Catherine Shaffer, The Motley Fool - Motley Fool - Wed Mar 26, 5:30PM CDT
Stock in Idera Pharmaceuticals tanked this week when Celgene announced that the FDA approved Otezla (apremilast) for psoriatic arthritis, a major competitor of Idera's Phase II candidate, IMO-8400. Both drugs face a crowded marketplace for...
Stock to Watch: Idera Pharmaceuticals Down 24.2% (IDRA)
Comtex SmarTrend(R) - Mon Mar 24, 10:11AM CDT
Idera Pharmaceuticals (NASDAQ:IDRA) is one of today's worst performing low-priced stocks, down 24.2% to $4.61 on 2.1x average daily volume. Thus far today, Idera Pharmaceuticals has traded 6.4 million shares, vs. average volume of 3.1 million shares per day. The stock has underperformed the Dow (-24.2% to the Dow's -0.2%) and underperformed the S&P 500 (-24.2% to the S&P's -0.6%) during today's trading.
Insider Buying Is On The Rise In These 4 Rallying Stocks
at The Street - Thu Mar 20, 5:16PM CDT
James Dennin, Kapitall: One way to evaluate small cap stocks is by looking for insider buying, when people on staff are buying [...]